Virchows Archiv

, Volume 462, Issue 1, pp 73–81

Tumoral indoleamine 2,3-dioxygenase expression predicts poor outcome in laryngeal squamous cell carcinoma

Authors

    • Department of Otolaryngology, Head and Neck SurgeryThe Third Affiliated Hospital of Sun Yat-Sen University
  • Hui Liu
    • Department of Internal Medicine, Division of Pulmonary and Critical CareThe Third Affiliated Hospital of Sun Yat-Sen University
  • Yanming Hu
    • Department of Otolaryngology, Head and Neck SurgeryAnhui Provincial Hospital
  • Peng Li
    • Department of Otolaryngology, Head and Neck SurgeryThe Third Affiliated Hospital of Sun Yat-Sen University
  • Gehua Zhang
    • Department of Otolaryngology, Head and Neck SurgeryThe Third Affiliated Hospital of Sun Yat-Sen University
  • Yuan Li
    • Department of Otolaryngology, Head and Neck SurgeryThe Third Affiliated Hospital of Sun Yat-Sen University
Original Article

DOI: 10.1007/s00428-012-1340-x

Cite this article as:
Ye, J., Liu, H., Hu, Y. et al. Virchows Arch (2013) 462: 73. doi:10.1007/s00428-012-1340-x

Abstract

The development of laryngeal squamous cell carcinomas (LSCC) is strongly influenced by the host immune system. Indoleamine 2,3-dioxygenase (IDO) can promote and maintain an immunosuppressive microenvironment which can impede the efficacy of anticancer responses. The purpose of the current study is to investigate the prognostic value of intratumoral IDO expression in LSCC. The expression of IDO protein was retrospectively assessed by immunohistochemistry in 187 LSCC patients. The potential association of tumor IDO expression with clinical parameters and tumor-infiltrating lymphocytes (TILs) was analyzed separately. Survival curves were estimated by the Kaplan–Meier method, and differences between groups were determined by log-rank test. Multivariate logistic regression analysis was performed to determine the independent factors associated with survival. Based on the evaluation score, 90 carcinomas (48.1 %) were identified with high IDO expression and 97 carcinomas (51.9 %) showed low expression. Tumor IDO expression was not associated with clinical stage, presence of metastases, and other clinicopathological parameters. Also, high IDO expression was not correlated with tumor-infiltrating CD3+ and CD8+ TILs. Instead it was positively related with the density of FOXP3+ Tregs. Furthermore, multivariate analysis identified a significant association of overall survival and disease-free survival with tumor IDO status. IDO high expression represents a significant negative prognostic factor in patients with LSCC. Current results provide further support for using IDO as an immunotherapeutic target in LSCC. The precise role of tumoral IDO in human LSCC remains to be elucidated in the future.

Keywords

Prognostic factorIndoleamine 2,3-dioxygenaseRegulatory T lymphocytesSquamous cell carcinomasTumor-infiltrating lymphocytes

Abbreviations

DFS

Disease-free survival

ESCC

Esophageal squamous cell carcinoma

FOXP3

Forkhead box P3

HPF

High power field

HNSCC

Head and neck squamous cell carcinomas

IHC

Immunohistochemistry

LSCC

Laryngeal squamous cell carcinomas

OS

Overall survival

OSCC

Oral squamous cell carcinomas

PL

Partial laryngectomy

RC

Radiochemotherapy

TIL

Tumor-infiltrating lymphocytes

TL

Total laryngectomy

Treg

Regulatory T lymphocytes

Copyright information

© Springer-Verlag Berlin Heidelberg 2012